EA201691894A1 - Лечение эпилептических расстройств у представителей кошачьих - Google Patents

Лечение эпилептических расстройств у представителей кошачьих

Info

Publication number
EA201691894A1
EA201691894A1 EA201691894A EA201691894A EA201691894A1 EA 201691894 A1 EA201691894 A1 EA 201691894A1 EA 201691894 A EA201691894 A EA 201691894A EA 201691894 A EA201691894 A EA 201691894A EA 201691894 A1 EA201691894 A1 EA 201691894A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cats
representatives
treatment
epileptic disorders
epileptic
Prior art date
Application number
EA201691894A
Other languages
English (en)
Other versions
EA036925B1 (ru
Inventor
Одило Рандольф Энгель
Анналена Михель
Фрерих Де-Врис
Original Assignee
Бёрингер Ингельхайм Ветмедика Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бёрингер Ингельхайм Ветмедика Гмбх filed Critical Бёрингер Ингельхайм Ветмедика Гмбх
Publication of EA201691894A1 publication Critical patent/EA201691894A1/ru
Publication of EA036925B1 publication Critical patent/EA036925B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Настоящее изобретение относится к применению 1-(4-хлорофенил)-4-(4-морфолинил)-2,5-дигидро-1Н-имидазол-2-она или его фармацевтически приемлемой соли в способе для лечения и/или предотвращения одного или более эпилептических расстройств у представителя кошачьих, предпочтительно кошек.
EA201691894A 2014-03-24 2015-03-20 Лечение эпилептических расстройств у представителей кошачьих EA036925B1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP2014055843 2014-03-24
EP2014059525 2014-05-09
EP14180415 2014-08-08
PCT/EP2015/055893 WO2015144576A1 (en) 2014-03-24 2015-03-20 Imepitoin for use in treating epileptic disorders in a feline

Publications (2)

Publication Number Publication Date
EA201691894A1 true EA201691894A1 (ru) 2017-03-31
EA036925B1 EA036925B1 (ru) 2021-01-15

Family

ID=52692648

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201691894A EA036925B1 (ru) 2014-03-24 2015-03-20 Лечение эпилептических расстройств у представителей кошачьих

Country Status (14)

Country Link
US (2) US9820988B2 (ru)
EP (1) EP3122361B1 (ru)
JP (1) JP6253804B2 (ru)
KR (1) KR102381504B1 (ru)
CN (1) CN106163525A (ru)
AU (1) AU2015238579B2 (ru)
CA (1) CA2943583C (ru)
DK (1) DK3122361T3 (ru)
EA (1) EA036925B1 (ru)
ES (1) ES2743544T3 (ru)
HU (1) HUE047174T2 (ru)
MX (1) MX369119B (ru)
PL (1) PL3122361T3 (ru)
WO (1) WO2015144576A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050070537A1 (en) 2002-10-10 2005-03-31 Chris Rundfeldt Use of dihydroimidazolones for the treatment of dogs
US9820988B2 (en) 2014-03-24 2017-11-21 Boehringer Ingelheim Vetmedica Gmbh Treatment of epileptic disorders in feline animals

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4044021A (en) 1971-10-21 1977-08-23 American Cyanamid Company Tetrasubstituted imidazolidine diuretics useful in the treatment of hyperaldosteronism
US3932452A (en) 1975-02-07 1976-01-13 Morton-Norwich Products, Inc. 1-Arylmethyl-2-imidazolidinones
US5869481A (en) 1995-09-05 1999-02-09 Arzneitmittelwerk Dresden G.M.B.H. Anticonvulsive 1-ar(alk)ylimidazolin-2-ones and process for making
DE19532668A1 (de) 1995-09-05 1997-03-06 Dresden Arzneimittel Neue, antikonvulsiv wirkende 1-Ar(alk)yl-imidazolin-2-one, die in 4-Stellung einen disubstituierten Amin-Rest enthalten, und Verfahren zu deren Herstellung
DE19721580A1 (de) 1997-05-23 1998-11-26 Dresden Arzneimittel Verwendung von 1-Ar(alk)yl-imidazolin-2-one zur Behandlung von Angst- und Spannungszuständen
JP2002507211A (ja) 1997-06-26 2002-03-05 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム ジヒドロホノキオール組成物の合成
JP4669095B2 (ja) 1999-07-19 2011-04-13 太陽化学株式会社 ペットの問題行動抑制組成物
EP1485094B2 (de) 2002-03-07 2020-03-25 Boehringer Ingelheim International GmbH Oral zu applizierende darreichungsform für 3- [(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino] -propionsäure-ethylester oder dessen salze
US20050070537A1 (en) 2002-10-10 2005-03-31 Chris Rundfeldt Use of dihydroimidazolones for the treatment of dogs
DE10339862A1 (de) 2003-08-29 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel
GB2487712B (en) * 2011-01-04 2015-10-28 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
KR20140057604A (ko) * 2011-08-12 2014-05-13 베링거잉겔하임베트메디카게엠베하 고양잇과 동물의 심부전을 치료 및 예방하는 방법에 사용하기 위한 퍼니 전류 억제제
US9820988B2 (en) 2014-03-24 2017-11-21 Boehringer Ingelheim Vetmedica Gmbh Treatment of epileptic disorders in feline animals

Also Published As

Publication number Publication date
MX369119B (es) 2019-10-30
AU2015238579B2 (en) 2019-09-19
JP2017508771A (ja) 2017-03-30
US20150265624A1 (en) 2015-09-24
EA036925B1 (ru) 2021-01-15
HUE047174T2 (hu) 2020-04-28
JP6253804B2 (ja) 2017-12-27
CA2943583A1 (en) 2015-10-01
MX2016012324A (es) 2017-01-06
AU2015238579A1 (en) 2016-08-04
KR102381504B1 (ko) 2022-04-04
ES2743544T3 (es) 2020-02-19
EP3122361B1 (en) 2019-07-03
US9820988B2 (en) 2017-11-21
US10420774B2 (en) 2019-09-24
CN106163525A (zh) 2016-11-23
WO2015144576A1 (en) 2015-10-01
US20180036316A1 (en) 2018-02-08
EP3122361A1 (en) 2017-02-01
DK3122361T3 (da) 2019-09-23
CA2943583C (en) 2022-08-16
PL3122361T3 (pl) 2019-12-31
KR20160128418A (ko) 2016-11-07

Similar Documents

Publication Publication Date Title
IL273824A (en) Methods of using ehmt2 inhibitors in the treatment or prevention of blood disorders
CL2016001715A1 (es) Nuevos inhibidores de glutaminasa
EA201691872A1 (ru) Гетероциклические соединения для применения в лечении pi3k-гамма-опосредованных расстройств
MX2018016046A (es) Quinazolina y compuestos indol para tratar trastornos medicos.
IL272444A (en) Compounds, their salts and methods for treating diseases
EA201790575A1 (ru) Триазолопиразиноны в качестве ингибиторов pde1
EA201790142A1 (ru) Лечение лейкоза ингибиторами гистондеацетилазы
NZ735000A (en) Methods for the treatment of abnormal involuntary movement disorders
EA201690881A1 (ru) Соединения-ингибиторы аутотаксина
CY1121806T1 (el) Ιμιδαζοπυραζινονες ως αναστολεις pde1
EA201692472A1 (ru) Соединения для лечения рака мозга
EA201792604A1 (ru) Ингибиторы аутотаксина и их применения
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
EA202091873A2 (ru) Способы лечения гипотонии
EA201791644A1 (ru) Ингибиторы mir-92 и их применение
EA201691567A1 (ru) Способы лечения легких травм головного мозга
EA201790156A1 (ru) Азетидинилоксифенилпирролидиновые соединения
EA201792610A1 (ru) Способ лечения неврологического заболевания
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
DK3307277T3 (da) Enkeltstrengede oligonukleotider til anvendelse i medicinsk behandling af hudlidelser
EA201691108A1 (ru) Хиназолин-thf-амины в качестве ингибиторов pde1
EA201792445A1 (ru) Новые амидогетероарилароилгидразидэтины
EA202090266A1 (ru) Ингибиторы mpo для применения в медицине
EA201691894A1 (ru) Лечение эпилептических расстройств у представителей кошачьих
EA201691335A1 (ru) Гексагидрофуропирролы в качестве ингибиторов pde1

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM